The items were successfully added to the cart.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Find out more


GLP-1 analogues have contributed significantly to the treatment of T2DM, as these therapies result in better glycemic control through a variety of mechanisms. GLP-1 may also be an interesting target for NAFLD and NASH therapies.

It has been demonstrated that the long-acting GLP-1 analogue Liraglutide decreases hepatic de novo lipogenesis in patients with NASH.Furthermore, Liraglutide significantly improves liver enzyme concentrations, hepatocyte ballooning, and histological steatosis, while also preventing progression of fibrosis.2

Liraglutide does not interfere in the Mercodia Total GLP-1 NL-ELISA which means that the ELISA assay is suitable for GLP-1 measurements even in samples from patients undergoing analogue treatment.  

  1. Armstrong MJ et al. (2016) J Hepatol 64: 399-408.
  2. Armstrong MJ et al. (2016) Lancet 387: 679-690.